{"SPADE_N_14046": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_14046", "Peptide Name": "Coleoptericin B (ZA-col B; natural AMPs; insects, arthropods, invertebrates, animals; UCLL1; BBMm)", "Source": "Zophobas atratus", "Family": "Not found", "Gene": "Not found", "Sequence": "SLQGGAPNFPQPSQQNGGWKVSPDLGRDDKGNTRGQIEIQNKGKDHDFNAGWGKVIRGPNKAKPTWHVGGTYRW", "Sequence Length": 74, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anti-inflammatory"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 8139.86, "PI": 9.99, "Hydrophobicity": -1.27, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Wang X, Li S, Du M, Liu N, Shan Q, Zou Y, Wang J, Zhu Y. 2024", "Reference": "J Antimicrob Chemother. 2024 Jan 4:dkad397. doi: 10.1093/jac/dkad397.PubMed", "Title": "A novel glycine-rich peptide from Zophobas atratus, coleoptericin B, targets bacterial membrane and protects against Klebsiella pneumoniae-induced mastitis in mice."}], "Frequent Amino Acids": "GKN", "Absent Amino Acids": "CMOU", "Basic Residues": 13, "Acidic Residues": 6, "Hydrophobic Residues": 24, "Polar Residues": 38, "Positive Residues": 13, "Negative Residues": 6, "Net Charge": 7, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (97.3%) toColeoptericinG: 18%. GRAVY: -1.27; mol Wt: 8139.955; mol formula: C359H555N107O106; mol ex coeff: 23690.Activity: active against E. coli ATCC 25922 (MIC 32 uM), K. pneumoniae CAU202084 (MIC 32 uM),  S. aureus ATCC 25923 (MIC 64 uM),  and S. haemolyticus CAU202078 (MIC 32 uM).SAR: Compared to the WT (AP00413), there are two aa changes: Q20K and R74W. These changes would make the peptide more active.Resistance development:no:bacteria:E. coli: Resistance development:no:bacteria:S. aureus ATCC 25923;  Resistance development:no:bacteria:K. pneumoniae;  Resistance development:no:bacteria:S. haemolyticus:: MIC to the four bacteria did not increase after 50 cycles (cf: gentamicin MIC > 128 ug/ml, MIC changed over 32-128 fold).MOA:bacteria: act on membranes. permeabilization.Toxicity: not toxic to RBC (not hemo.lytic) or vero cells at 128 uM.Recombinant production:bacteria:Escherichia coli: expressed as a GST fusion, purified by GSTrap 4B, PreScission Protease cleavage, further purified by Superdex 30.Animal model:mouse: challenge with K. pneumoniae CAU202084 for 27 h caused mastitis and treatment with the peptide or  gentamicin effectively reduced\nneutrophil infiltration and alleviated the thickening of acinar walls. CFU reduced ~1 log. In addition, both TNF-alpha and IL-1beta reduced in the peptide treated group relative to the infected group (Anti-inflammatory).", "Similar Sequences": [{"SPADE_ID": "SPADE_N_02397", "Similarity": 0.972972972972973, "Sequence": "SLQGGAPNFPQPSQQNGGWQVSPDLGRDDKGNTRGQIEIQNKGKDHDFNAGWGKVIRGPNKAKPTWHVGGTYRR"}, {"SPADE_ID": "SPADE_N_02403", "Similarity": 0.6619718309859155, "Sequence": "SLQPGAPNVNNKDQPWQVSPHISRDDSGNTNTDINLQRHGENHDFDAGWSKVVRGPNKAKPTWHVGGTYRW"}, {"SPADE_ID": "SPADE_N_02400", "Similarity": 0.6338028169014085, "Sequence": "SLQPGAPNVNNKDQPWQVSPHISRDDSGNTRTDINVQRHGENNDFEAGWSKVVRGPNKAKPTWHIGGTHRW"}]}}}